2-Naphthylmethcathinone

BMAPN
Clinical data
Other namesBMAPN; βk-Methamnetamine
Legal status
Legal status
Identifiers
  • 2-(methylamino)-1-(naphthalene-2-yl) propan-1-one
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC14H15NO
Molar mass213.280 g·mol−1
3D model (JSmol)
  • CC(C(=O)C1=CC2=CC=CC=C2C=C1)NC
  • InChI=1S/C14H15NO/c1-10(15-2)14(16)13-8-7-11-5-3-4-6-12(11)9-13/h3-10,15H,1-2H3
  • Key:QIMNQDXLKHGANJ-UHFFFAOYSA-N

2-Naphthylmethcathinone (BMAPN), also known as βk-methamnetamine, is a stimulant drug of the cathinone and naphthylaminopropane families. It inhibits dopamine reuptake and has rewarding and reinforcing properties in animal studies. It is banned under drug analogue legislation in a number of jurisdictions. The drug was at one point marketed under the name NRG-3, although only a minority of samples of substances sold under this name have been found to actually contain BMAPN, with most such samples containing mixtures of other cathinone derivatives.

Monoamine release of BMAPN and related agents (EC50Tooltip Half maximal effective concentration, nM)
Compound NETooltip Norepinephrine DATooltip Dopamine 5-HTTooltip Serotonin Ref
d-Amphetamine 6.6–10.2 5.8–24.8 698–1,765
Naphthylaminopropane (NAP; PAL-287) 11.1 12.6 3.4
d-Methamphetamine 12.3–14.3 8.5–40.4 736–1,292
Methylnaphthylaminopropane (MNAP; PAL-1046) 34 10 13
l-Methcathinone 13.1 14.8 1,772
2-Naphthylmethcathinone (BMAPN; βk-MNAP) 94% at 10 μM 34 27
d-Ethylamphetamine 28.8 44.1 333.0
Ethylnaphthylaminopropane (ENAP; PAL-1045) 137 46 a 12 a
Phenmetrazine 29–50.4 70–131 7,765–>10,000
Naphthylmetrazine (PAL-704) 203 111 RI (105)
Notes: The smaller the value, the more strongly the drug releases the neurotransmitter. The assays were done in rat brain synaptosomes and human potencies may be different. See also Monoamine releasing agent § Activity profiles for a larger table with more compounds. Footnotes: a ENAPTooltip Ethylnaphthylaminopropane is a partial releaser of serotonin (EmaxTooltip maximal efficacy = 66%) and dopamine (Emax = 78%). Refs: